Surrozen secures FDA clearance for SZN-8141 and $95.1 million financing

• Surrozen received U.S. FDA clearance for its investigational new drug application for SZN-8141 to treat diabetic macular edema.
• The regulatory clearance satisfies the closing milestone for a private placement, expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026.
• The company stated it plans to dose the first patient in its Phase 1b/2a DUET clinical trial in the fourth quarter of 2026.

Surrozen (NASDAQ:SRZN) received U.S. FDA clearance of its investigational new drug application for SZN-8141, enabling clinical development for diabetic macular edema.

The company expects to dose the first patient in the DUET Phase 1b/2a clinical study during the fourth quarter of 2026.

The regulatory clearance successfully satisfies the milestone requirement for the second closing of the company's March 2025 two-tranche private placement.

Surrozen expects the financing to close on or about October 20, 2026, subject to customary closing conditions.

The transaction is expected to provide approximately $95.1 million in gross proceeds before placement agent fees and other related expenses.

The issued securities under the private placement include common shares, pre-funded warrants, and Series E common stock warrants.